Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

AFJK vs CANG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AFJK
Aimei Health Technology Co., Ltd

Shell Companies

Financial ServicesNASDAQ • US
Market Cap$261M
5Y Perf.+319.2%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$250M
5Y Perf.-9.8%

AFJK vs CANG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AFJK logoAFJK
CANG logoCANG
IndustryShell CompaniesAuto - Dealerships
Market Cap$261M$250M
Revenue (TTM)$0.00$3.46B
Net Income (TTM)$1M$-178M
Gross Margin13.6%
Operating Margin7.3%
Forward P/E251.0x5.7x
Total Debt$2M$170M
Cash & Equiv.$3K$1.29B

AFJK vs CANGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AFJK
CANG
StockJan 24May 26Return
Aimei Health Techno… (AFJK)100419.2+319.2%
Cango Inc. (CANG)10090.2-9.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: AFJK vs CANG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AFJK leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Cango Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
AFJK
Aimei Health Technology Co., Ltd
The Banking Pick

AFJK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 0.23
  • 320.4% 10Y total return vs CANG's -44.9%
  • Lower volatility, beta 0.23, Low D/E 25.2%, current ratio 0.00x
Best for: income & stability and long-term compounding
CANG
Cango Inc.
The Growth Play

CANG is the clearest fit if your priority is growth exposure.

  • Rev growth -52.7%, EPS growth 9.6%, 3Y rev CAGR -41.0%
  • -52.7% revenue growth vs AFJK's -57.2%
  • Lower P/E (5.7x vs 251.0x)
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCANG logoCANG-52.7% revenue growth vs AFJK's -57.2%
ValueCANG logoCANGLower P/E (5.7x vs 251.0x)
Stability / SafetyAFJK logoAFJKBeta 0.23 vs CANG's 2.25
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)AFJK logoAFJK+288.0% vs CANG's -73.7%
Efficiency (ROA)AFJK logoAFJK2.9% ROA vs CANG's -2.3%, ROIC -1.5% vs 4.6%

AFJK vs CANG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AFJKAimei Health Technology Co., Ltd

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M

AFJK vs CANG — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCANGLAGGINGAFJK

Income & Cash Flow (Last 12 Months)

CANG leads this category, winning 1 of 1 comparable metric.

CANG and AFJK operate at a comparable scale, with $3.5B and $0 in trailing revenue.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
RevenueTrailing 12 months$0$3.5B
EBITDAEarnings before interest/tax-$835,759$333M
Net IncomeAfter-tax profit$1M-$178M
Free Cash FlowCash after capex-$565,100$0
Gross MarginGross profit ÷ Revenue+13.6%
Operating MarginEBIT ÷ Revenue+7.3%
Net MarginNet income ÷ Revenue-5.2%
FCF MarginFCF ÷ Revenue-154.0%
Rev. Growth (YoY)Latest quarter vs prior year+58.3%
EPS Growth (YoY)Latest quarter vs prior year-59.1%+3.6%
CANG leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

CANG leads this category, winning 2 of 2 comparable metrics.

At 5.7x trailing earnings, CANG trades at a 98% valuation discount to AFJK's 251.0x P/E.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
Market CapShares × price$261M$250M
Enterprise ValueMkt cap + debt − cash$263M$85M
Trailing P/EPrice ÷ TTM EPS251.03x5.66x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple3.13x
Price / SalesMarket cap ÷ Revenue2.12x
Price / BookPrice ÷ Book value/share21.48x0.42x
Price / FCFMarket cap ÷ FCF
CANG leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

CANG leads this category, winning 5 of 8 comparable metrics.

AFJK delivers a 3.2% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-4 for CANG. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to AFJK's 0.25x. On the Piotroski fundamental quality scale (0–9), CANG scores 4/9 vs AFJK's 2/9, reflecting mixed financial health.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
ROE (TTM)Return on equity+3.2%-4.1%
ROA (TTM)Return on assets+2.9%-2.3%
ROICReturn on invested capital-1.5%+4.6%
ROCEReturn on capital employed-2.0%+4.5%
Piotroski ScoreFundamental quality 0–924
Debt / EquityFinancial leverage0.25x0.04x
Net DebtTotal debt minus cash$2M-$1.1B
Cash & Equiv.Liquid assets$2,929$1.3B
Total DebtShort + long-term debt$2M$170M
Interest CoverageEBIT ÷ Interest expense-1.87x
CANG leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

AFJK leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in AFJK five years ago would be worth $42,044 today (with dividends reinvested), compared to $8,579 for CANG. Over the past 12 months, AFJK leads with a +288.0% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors AFJK at 61.4% vs CANG's 0.4% — a key indicator of consistent wealth creation.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
YTD ReturnYear-to-date-43.7%-62.0%
1-Year ReturnPast 12 months+288.0%-73.7%
3-Year ReturnCumulative with dividends+320.4%+1.2%
5-Year ReturnCumulative with dividends+320.4%-14.2%
10-Year ReturnCumulative with dividends+320.4%-44.9%
CAGR (3Y)Annualised 3-year return+61.4%+0.4%
AFJK leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

AFJK leads this category, winning 2 of 2 comparable metrics.

AFJK is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than CANG's 2.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AFJK currently trades 32.7% from its 52-week high vs CANG's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
Beta (5Y)Sensitivity to S&P 5000.23x2.25x
52-Week HighHighest price in past year$130.37$2.88
52-Week LowLowest price in past year$6.75$0.33
% of 52W HighCurrent price vs 52-week peak+32.7%+18.6%
RSI (14)Momentum oscillator 0–10054.258.6
Avg Volume (50D)Average daily shares traded21K1.3M
AFJK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$3.00
# AnalystsCovering analysts2
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises5
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%
Insufficient data to determine a leader in this category.
Key Takeaway

CANG leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). AFJK leads in 2 (Total Returns, Risk & Volatility).

Best OverallCango Inc. (CANG)Leads 3 of 6 categories
Loading custom metrics...

AFJK vs CANG: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is AFJK or CANG a better buy right now?

Cango Inc.

(CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AFJK or CANG?

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 5. 7x versus Aimei Health Technology Co. , Ltd at 251. 0x.

03

Which is the better long-term investment — AFJK or CANG?

Over the past 5 years, Aimei Health Technology Co.

, Ltd (AFJK) delivered a total return of +320. 4%, compared to -14. 2% for Cango Inc. (CANG). Over 10 years, the gap is even starker: AFJK returned +320. 4% versus CANG's -44. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AFJK or CANG?

By beta (market sensitivity over 5 years), Aimei Health Technology Co.

, Ltd (AFJK) is the lower-risk stock at 0. 23β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 864% more volatile than AFJK relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 25% for Aimei Health Technology Co. , Ltd — giving it more financial flexibility in a downturn.

05

Which is growing faster — AFJK or CANG?

On earnings-per-share growth, the picture is similar: Cango Inc.

grew EPS 960. 0% year-over-year, compared to -39. 3% for Aimei Health Technology Co. , Ltd. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AFJK or CANG?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus 0. 0% for Aimei Health Technology Co. , Ltd — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus 0. 0% for AFJK. At the gross margin level — before operating expenses — CANG leads at 55. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Which pays a better dividend — AFJK or CANG?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is AFJK or CANG better for a retirement portfolio?

For long-horizon retirement investors, Aimei Health Technology Co.

, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +320. 4% 10Y return). Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AFJK: +320. 4%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between AFJK and CANG?

These companies operate in different sectors (AFJK (Financial Services) and CANG (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AFJK is a small-cap quality compounder stock; CANG is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

AFJK

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AFJK and CANG on the metrics below

P/E Ratio<
x
(AFJK: 251.0x · CANG: 5.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.